摘要 |
<p>The present disclosure is directed to the use of naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition in unit dose form, wherein said esomeprazole, or pharmaceutically acceptable salt thereof, is released from said unit dose form at a specified pH, wherein one unit dose form is for administration as an AM dose and a second unit dose form is for administration about 10 hours later as a PM dose to target a specified pharmacokinetic profile.</p> |